Overview
I am convinced that caring for patients with malignant hematologic diseases requires not only up-to-date medical knowledge, but also an understanding of the individual patient's needs and circumstances. I encourage patients to take an active role in their treatment and recovery and I work with them to develop an individualized treatment plan that includes the most advanced therapies available today. My practice focuses primarily on disorders of the lymphatic system (Hodgkin and non-Hodgkin lymphoma and chronic lymphocytic leukemia). As an integral part of my clinical activities, I am dedicated to teaching young physicians at all levels of training and educating the next generation of hematologists.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Recent Publications
Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
Conference Blood · November 5, 2024 Introduction: Chimeric Antigen Receptor (CAR)- T cell therapy has revolutionized the treatment of hematologic malignancies. However, access to CAR-T therapy remains limited, especially fo ... Full text CiteCutaneous Vasculopathy and Recalcitrant Lower-Extremity Ulcerations
Journal Article Annals of Internal Medicine Clinical Cases · April 1, 2023 Lower-extremity ulcerations are a frequent cause of hospitalization, and those that persist despite appropriate treatment warrant careful scrutiny. We present a case of chronic, progressive leg ulcerations in a young woman accompanied by oral and genital u ... Full text CiteAn international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Journal Article Blood Adv · April 12, 2022 Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which be ... Full text Link to item CiteEducation, Training & Certifications
University of Cologne, Faculty of Medicine (Germany) ·
1999
M.D.